|Other Names||Bcl-2-binding component 3, JFY-1, p53 up-regulated modulator of apoptosis, BBC3, PUMA|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1317a was selected from the region of human Puma BH3 Domain. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Essential mediator of p53/TP53-dependent and p53/TP53- independent apoptosis (PubMed:11463391). Functions by promoting partial unfolding of BCL2L1 and dissociation of BCL2L1 from p53/TP53. Regulates ER stress-induced neuronal apoptosis (PubMed:23340338).|
|Cellular Location||Mitochondrion Note=Localized to the mitochondria in order to induce cytochrome c release|
|Tissue Location||Ubiquitously expressed.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PUMA is one of the pro-apoptotic Bcl-2 family members including Bax and Noxa, which are also transcriptional targets of p53. The PUMA gene encodes two BH3 domain-containing proteins termed PUMA-a and PUMA-b. PUMA proteins bind Bcl-2, localize to the mitochondria, and induce cytochrome c release and apoptosis in response to p53. PUMA may be a direct mediator of p53-induced apoptosis.
Liu, F.T., et al., Biochem. Biophys. Res. Commun. 310(3):956-962 (2003).Hoque, M.O., et al., Cancer Lett. 199(1):75-81 (2003).Yu, J., et al., Proc. Natl. Acad. Sci. U.S.A. 100(4):1931-1936 (2003).Han, J., et al., Proc. Natl. Acad. Sci. U.S.A. 98(20):11318-11323 (2001).Nakano, K., et al., Mol. Cell 7(3):683-694 (2001).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.